Evidence map›Paper›PMID 39962532›Full record

ArticleBreast cancer research : BCR2025

Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer.

Natasha B Hunter, Lanell M Peterson, Jennifer M Specht, David A Mankoff, Mark Muzi, Delphine L Chen, William R Gwin, Shaveta Vinayak, Nancy E Davidson, Hannah M Linden

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Natasha B HunterUniversity of Washington, Seattle, WA, USA.
Lanell M PetersonUniversity of Washington, Seattle, WA, USA. lanell@uw.edu.
Jennifer M SpechtUniversity of Washington, Seattle, WA, USA.
David A MankoffUniverstity of Pennsylvania, Philadelphia, PA, USA.
Mark MuziUniversity of Washington, Seattle, WA, USA.
Delphine L ChenUniversity of Washington, Seattle, WA, USA.
William R GwinUniversity of Washington, Seattle, WA, USA.
Shaveta VinayakUniversity of Washington, Seattle, WA, USA.
Nancy E DavidsonUniversity of Washington, Seattle, WA, USA.
Hannah M LindenUniversity of Washington, Seattle, WA, USA.

Funding

RadiochemistryP01CA042045 · NCI · UNIVERSITY OF WASHINGTON · PI EARY, JANET F. · 1986 to 2015
$23.2M
IMAGING THE RESPONSE OF LOCALLY ADVANCED BREAST CANCERR01CA072064 · NCI · UNIVERSITY OF WASHINGTON · PI MANKOFF, DAVID A. · 1996 to 2006
$3.1M
Core Laboratory for Advanced PET and MRI image analysisR50CA211270 · NCI · UNIVERSITY OF WASHINGTON · PI Mark Muzi · 2017 to 2026
$2.6M
NCI NIH HHS P01 CA042045NCI NIH HHS R01 CA072064NCI NIH HHS R50 CA211270NIH HHS CA42045NIH HHS CA72064
6 · The paper itself

Abstract

background

methodsWe conducted a retrospective study examining uptake in matched lesions for FES and FDG-PET scans, assessing these parameters in 213 patients with ER-positive/HER2-positive (n = 33) versus ER-positive/HER2-negative MBC (n = 180). We employed log-rank and t-tests to assess the association of HER2 status with outcome variables and the hypotheses that patients expressing HER2-positive disease lived longer than patient with HER2-negative disease.

resultsNo difference in FES or FDG avidity was observed between patients with HER2-negative or HER2-positive tumor status. Limited data also suggests that patients with HER2-positive disease had better overall survival (p = 0.024), than those with HER2-negative disease, but not time-to-progression between the same patient cohorts.

conclusionThis retrospective analysis suggests that there is a possible role for future trials using FES-PET in helping to select patients with ER+/HER2-positive primary tumors who retain ER expression at all sites of disease and may benefit from endocrine therapy.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesEstradiolFluorodeoxyglucose F18Positron-Emission TomographyReceptors, EstrogenAdultAgedAged, 80 and overFemaleHumansMiddle AgedNeoplasm MetastasisPrognosisRadiopharmaceuticalsRetrospective StudiesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesEstradiolFluorodeoxyglucose F18RadiopharmaceuticalsReceptors, EstrogenFDG-PETFES-PETHER2Metastatic breast cancer

Identifiers

PMID39962532
PMCPMC11834562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.